Drug intelligence / Profile preview

BRY102

Development stage: Preclinical
Lead developer: Bryleos
Modality: Small Molecules
Administration: Oral

Overview

BRY102 is an oral small molecule candidate in preclinical development by Bryleos for the treatment of neurodegenerative diseases and rare neurological disorders. Developed using Bryleos's proprietary LathMize® green platform technology, BRY102 is designed to target endpoints related to the oxidative stress pathway. The LathMize® platform utilizes a waterless, solvent-free green chemistry approach to enhance the stability, metabolic resilience, and oral bioavailability of endogenous molecules, enabling them to cross the blood-brain barrier and target cellular health.

Beyond the preview

Go deeper on BRY102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRY102.

Explore the full profile